What's Happening?
Precision BioSciences has announced significant findings from its ELIMINATE-B study, showcasing the potential of its PBGENE-HBV gene editing program to treat chronic hepatitis B. The study, presented at the European Association for the Study of the Liver
Congress 2026, revealed that PBGENE-HBV effectively eliminates cccDNA, the root cause of hepatitis B viral replication. The treatment demonstrated a 10-fold reduction in cccDNA-derived transcripts and achieved pgRNA loss in all patients with detectable levels at baseline. The program, which has received Fast Track designation from the FDA, aims to provide a curative treatment for hepatitis B, moving beyond lifelong viral suppression to a finite, biomarker-guided cure.
Why It's Important?
This development marks a significant advancement in the treatment of chronic hepatitis B, a condition that affects millions worldwide and currently lacks a curative therapy. The ability of PBGENE-HBV to directly target and eliminate cccDNA could transform the management of hepatitis B, reducing the need for lifelong medication and improving patient outcomes. The study's findings align with FDA guidance on the desired endpoint for hepatitis B treatments, potentially paving the way for regulatory approval. This breakthrough could lead to a paradigm shift in how chronic hepatitis B is treated, offering hope for a complete viral cure.
What's Next?
Precision BioSciences plans to expand the ELIMINATE-B trial, increasing patient enrollment and collecting additional data to support the program's efficacy and safety. The company aims to optimize dosing schedules and explore the potential for nucleoside analog withdrawal. Further updates on the trial are expected by the end of 2026. The success of PBGENE-HBV could stimulate further research and development in gene editing therapies for other viral and genetic diseases, potentially leading to new treatment options for conditions that currently have limited therapeutic solutions.
